Breaking News, Collaborations & Alliances

Crown Bioscience Enters Antibody Collaboration

Will develop a CTLA-4 antibody with Jiangsu Qyun Bio-Pharmaceutical

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crown Bioscience will collaborate to develop a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody with Jiangsu Qyun Bio-Pharmaceutical. CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals’ expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio’s proprietary 10B10 antibody. “The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical is indicative of our focus on innovation, and enhances our portfolio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters